|
KMID : 0980320190190020091
|
|
Journal of Dental Anesthesia and Pain Medicine
2019 Volume.19 No. 2 p.91 ~ p.99
|
|
|
Remifentanil promotes osteoblastogenesis by upregulating Runx2/osterix expression in preosteoblastic C2C12 cells
|
|
Yoon Ji-Young
Kim Tae-Sung
Ahn Ji-Hye
Yoon Ji-Uk
Kim Hyung-Joon
Kim Eun-Jung
|
|
|
Abstract
|
|
|
Background: The imbalance between osteoblasts and osteoclasts can lead to pathological conditions such as osteoporosis. It has been reported that opioid adversely affect the skeletal system, but it is inconsistent. Remifentanil is currently used as an adjuvant analgesic drug in general anesthesia and sedation. The aim of the present study was to investigate the effect of remifentanil on the osteoblast differentiation and mechanism involved in this effect.
Methods: The C2C12 cells (mouse pluripotent mesenchymal cell line) were used as preosteoblast. Osteoblastic differentiation potency was determined by alkaline phosphatase (ALP) staining. C2C12 cell migration by remifentanil was evaluated using Boyden chamber migration assay. The expression of Runx2 and osterix was evaluated by RT-PCT and western blot analysis to investigate the mechanism involved in remifentanil-mediated osteoblast differentiation.
Results: ALP staining showed that remifentanil increased significantly osteoblast differentiation. In Boyden chamber migration assay, C2C12 cell migration was increased by remifentanil. RT-PCR and western blot analysis showed that the expression of Runx2 and osterix was upregulated by remifentanil.
Conclusions: We demonstrated that remifentanil increased osteoblast differentiation in vitro by upregulation of Runx2 and osterix expression. Therefore, remifentanil has the potential for assisting with bone formation and bone healing.
|
|
|
KEYWORD
|
|
|
Osteoblasts, Osterix, Remifentanil, Runx2
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
|